7 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33937953 | The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants. | 2021 Oct | 4 |
2 | 34021354 | Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity. | 2021 Aug 3 | 2 |
3 | 31728714 | The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. | 2020 Feb | 3 |
4 | 31863284 | The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. | 2020 Feb | 3 |
5 | 32399810 | Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. | 2020 Jun | 2 |
6 | 30660696 | Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. | 2019 Mar | 4 |
7 | 29744867 | P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. | 2018 Oct 15 | 2 |